Search results for "Growth factor"

showing 10 items of 1300 documents

POOLED ESTIMATES OF INCIDENCE OF ENDOPHTHALMITIS AFTER INTRAVITREAL INJECTION OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS WITH AND WITHOUT TOPI…

2017

Purpose: To assess the effect of topical antibiotic prophylaxis on postoperative endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.Methods: A systematic literature search was performed from inception to March 2016 using PubMed, Medline, Web of Science, Embase, and the Cochrane Library, to identify articles that reported cases of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents. We used a pooled analysis to estimate the incidence of cases of endophthalmitis who developed after injections performed with and without topical antibiotic prophylaxis. We used regression analysis to explore the effects of stu…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyEye InfectionsVisual AcuityAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection;Angiogenesis InhibitorsCochrane LibraryGlobal HealthEye Infections Bacteriallaw.invention03 medical and health sciencestopical antibiotic prophylaxis; postoperative endophthalmitis; anti–vascular endothelial growth factor agents; intravitreal injectionpostoperative endophthalmitis0302 clinical medicineEndophthalmitisRandomized controlled triallawtopical antibiotic prophylaxisanti–vascular endothelial growth factor agentsInternal medicinemedicineantibiotic prophylaxiHumansanti-vascular endothelial growth factor030212 general & internal medicineAntibiotic prophylaxisProspective cohort studyAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection; Angiogenesis Inhibitors; Anti-Bacterial Agents; Endophthalmitis; Eye Infections Bacterial; Global Health; Humans; Intravitreal Injections; Vascular Endothelial Growth Factor A; Antibiotic Prophylaxis; Visual AcuityEndophthalmitisbusiness.industryIncidence (epidemiology)Bacterialintravitreal injectionRetrospective cohort studyGeneral MedicineEye infectionAntibiotic Prophylaxismedicine.diseaseAntibiotic prophylaxis; Anti–vascular endothelial growth factor; Endophthalmitis; Intravitreal injection; Angiogenesis Inhibitors; Anti-Bacterial Agents; Endophthalmitis; Eye Infections; Bacterial; Global Health; Humans; Intravitreal Injections; Vascular Endothelial Growth Factor A; Antibiotic Prophylaxis; Visual AcuitySurgeryAnti-Bacterial AgentsOphthalmologyendophthalmitiIntravitreal Injections030221 ophthalmology & optometryAnti–vascular endothelial growth factorbusiness
researchProduct

From the oxygen to the organ protection: Erythropoietin as protagonist in internal medicine

2006

Erythropoietin (EPO), already known as the stimulating hormone for erythropoiesis, has shown different and interesting pleiotropic actions. It does not only affect erythroid cells, but also myeloid cells, lymphocytes and megakaryocytes. This hormone can also enhance phagocytic function of the polymorphonuclear cells and reduce the activation of macrophages, thus modulating the inflammatory process.Moreover, hematopoietic and endothelial cells probably have the same cellular origin, and the discovery of erythropoietin receptors (EPO-R) also on mesangial and myocardial cells, smooth muscle fibrocells and neurons has prompted the study of the non-erythropoietic functions of this hormone.The in…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyIschemiaNeovascularizationIschemiahemic and lymphatic diseasesInternal medicinemedicineErythropoietin (EPO); pleiotropic actions; erythropoietin receptors (EPO-R); VEGFHumansOxygen tensionReceptorHypoxiaErythropoietinPharmacologyClinical Trials as Topicbusiness.industryPleiotropic actionerythropoietin receptors (EPO-R)pleiotropic actionsAngiogenesis Modulating AgentsApoptosiAnemiaShockHematologymedicine.diseaseVEGFHaematopoiesisAngiogenesiEndocrinologyApoptosisErythropoietinErythropoietin (EPO)Erythropoiesismedicine.symptombusinessCardiology and Cardiovascular MedicineHormonemedicine.drugReceptor
researchProduct

Obesity and intermittent hypoxia increase tumor growth in a mouse model of sleep apnea.

2012

Background: Intermittent hypoxia and obesity which are two pathological conditions commonly found in patients with obstructive sleep apnea (OSA), potentially enhance cancer progression. Objective: To investigate whether obesity and/or intermittent hypoxia (IH) mimicking OSA affect tumor growth. Methods: A subcutaneous melanoma was induced in 40 mice [22 obese (40–45 g) and 18 lean (20–25 g)] by injecting 106 B16F10 cells in the flank. Nineteen mice (10 obese/9 lean) were subjected to IH (6 h/day for 17 days). A group of 21 mice (12 obese/9 lean) were kept under normoxia. At day 17, tumors were excised, weighed and processed to quantify necrosis and endothelial expression of vascular endothe…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyNecrosisMice ObeseSettore MED/10 - Malattie Dell'Apparato Respiratoriochemistry.chemical_compoundMiceSleep Apnea SyndromesInternal medicineMedicineAnimalsAnimal modelTumor growthObesityHypoxiaMelanomaCancerIntermittent hypoxiabusiness.industryMelanomaSleep apneaSleep apneaCancerIntermittent hypoxiaGeneral Medicinemedicine.diseaseObesityObstructive sleep apneaVascular endothelial growth factorMice Inbred C57BLDisease Models AnimalEndocrinologychemistrymedicine.symptombusinessNeoplasm TransplantationSleep medicine
researchProduct

Priming with a combination of proangiogenic growth factors improves wound healing in normoglycemic mice

2011

Growth factors and/or angiogenic factors are supposed to improve wound healing. The aim of our study was to evaluate the effects of subcutaneous pretreatment with combinatory proangiogenic factors on wound closure, mechan - ical properties, vessel density and morphology. Twenty-eight Balb/c mice were divided equally into two groups. A mixture of VEGF (35.0 µg), bFGF (2.5 µg) and P dGF (3.5 µg) was administered subcutaneously 3, 5 and 7 days to 14 mice before full thickness skin punch biopsy wounding, whereas 14 control animals received three injections of 0.2 ml saline solution. Wound sizes were assessed daily and the repaired tissues were harvested 7 days after complete wound closure. Comp…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyPlatelet-derived growth factormedicine.medical_treatmentInjections SubcutaneousUrologyPriming (immunology)Neovascularization PhysiologicArticlechemistry.chemical_compoundMiceSkin Physiological PhenomenaTensile StrengthGeneticsmedicineAnimalsRegenerationSalineSkinPlatelet-Derived Growth FactorMice Inbred BALB CWound HealingOncogeneintegumentary systembusiness.industryGeneral MedicineMolecular medicineSurgeryVascular endothelial growth factor ADrug CombinationsCollagen Type IIIchemistryApoptosisThermographyBlood VesselsAngiogenesis Inducing AgentsFemaleFibroblast Growth Factor 2Wound healingbusiness
researchProduct

Protein kinase C   promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor

2008

Aims Protein kinase C (PKC) plays an important role in the regulation of angiogenesis. However, downstream targets of PKC in endothelial cells are poorly defined. Methods and results mRNA expression of vascular endothelial growth factor (VEGF) was analysed by quantitative real-time RT-PCR in human umbilical vein endothelial cells (HUVEC) and HUVEC-derived EA.hy 926 cells. siRNA was used to knockdown PKC isoforms and VEGF. Matrigel tube formation assay was used to analyse the angiogenic activity of endothelial cells. Phorbol-12-myristate-13-acetate (PMA) enhanced the ability of HUVEC to organize into tubular networks when plated on Matrigel, a phenomenon that could be prevented by PKC inhibi…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyProtein Kinase C-alphaTime FactorsPhysiologyAngiogenesismedicine.medical_treatmentBlotting WesternCarbazolesNeovascularization PhysiologicBiologyPolymerase Chain ReactionCell Linechemistry.chemical_compoundPhysiology (medical)Internal medicinemedicineHumansRNA MessengerRNA Small InterferingCell ShapeProtein Kinase InhibitorsCells CulturedProtein kinase CTube formationMatrigelStem CellsGrowth factorEndothelial CellsUp-RegulationCell biologyEnzyme ActivationEndothelial stem cellVascular endothelial growth factorAutocrine CommunicationVascular endothelial growth factor AReceptors Vascular Endothelial Growth FactorEndocrinologychemistryTetradecanoylphorbol AcetateAngiogenesis Inducing AgentsFibroblast Growth Factor 2RNA InterferenceCardiology and Cardiovascular MedicineCardiovascular Research
researchProduct

Priming with a Combination of Proangiogenic Growth Factors Enhances Wound Healing in Streptozotocin-Induced Diabetes in Mice

2010

<i>Background:</i> Numerous proangiogenic growth factors have been shown to improve impaired wound healing. This study evaluated the effects of subcutaneous pretreatment with a combination of proangiogenic growth factors on wound closure, mechanical properties, vessel density, and morphology. <i>Methods:</i> Thirty-six Balb/c mice with streptozotocin-induced diabetes were divided into 3 groups. A mixture of VEGF (35.0 µg), bFGF (2.5 µg), and PDGF (3.5 µg) was administered subcutaneously 3, 5, and 7 days prior to wounding in the first group, whereas the second group received three doses of 3.5 µg PDGF. Wound sizes were assessed daily and the repaired tissues were harv…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyVEGF receptorsNeovascularization PhysiologicPriming (immunology)PharmacologyDiabetes Mellitus ExperimentalDiabetes ComplicationsMiceTensile StrengthDiabetes mellitusAnimalsMedicineAngiogenic ProteinsSkinPlatelet-Derived Growth FactorMice Inbred BALB CWound Healingbiologybusiness.industrymedicine.diseaseStreptozotocinSurgeryWound areaDiabetic wound healingbiology.proteinFemaleFibroblast Growth Factor 2SurgeryCollagenSkin TemperaturebusinessWound healingPlatelet-derived growth factor receptormedicine.drugEuropean Surgical Research
researchProduct

Intravitreal dexamethasone implant versus anti-vascular endothelial growth factor therapy combined with cataract surgery in patients with diabetic ma…

2021

Objective: to compare outcomes of cataract surgery combined with either anti-Vascular Endothelial Growth Factor (anti-VEGF) therapy or dexamethasone implant (DEX) in patients with diabetic macular oedema (DMO). Methods: Pubmed and Embase databases were searched for studies reporting outcomes of diabetic cataract surgery combined with either anti-VEGF or DEX, with a follow-up ≥3 months. The primary outcome was the mean change in central macular thickness (CMT). Mean change in best corrected visual acuity (BCVA) was considered as a secondary outcome. The mean difference between baseline and post-treatment values (MD) with 95%-Confidence Interval (95%CI) was calculated and meta-analyses were p…

Vascular Endothelial Growth Factor Amedicine.medical_specialtygenetic structuresmedicine.medical_treatmentVisual AcuityEndothelial Growth FactorsMacular EdemaDexamethasoneCataractOphthalmologyDiabetes MellitusHumansMedicineIn patientDexamethasoneDiabetic Retinopathybusiness.industryDEXcataract surgeryCataract surgeryDiabetic cataractBevacizumabOphthalmologyAnti–vascular endothelial growth factor therapyDiabetic macular oedemaanti-VEGFdiabetic macular oedemaMeta-analysissense organsImplantbusinessmedicine.drugEye
researchProduct

Modification of xenogenic bone substitute materials - effects on the early healing cascadein vitro

2013

Introduction Initial platelet activation with subsequent cytokine release at the defect site plays a crucial role in tissue integration. The aim of this study was to evaluate the influence of topographic and biomimetic collagen modifications of a xenogenic bone substitute material (BSM) on in vitro platelet activation and cytokine release. Material and Methods Three types of xenogenic BSM were used. Two BSM with different levels of granularity (large granule BSM [XBSM/L], small granule BSM [XBSM/S]) and a BSM with collagen (XBSM/C). All three samples were incubated with platelet concentrate of four healthy volunteers at room temperature for 15 min. For all groups, highly thrombogenic collag…

Vascular Endothelial Growth Factor Amedicine.medical_specialtymedicine.medical_treatmentEnzyme-Linked Immunosorbent AssayIn Vitro TechniquesBiomimetic MaterialsTransforming Growth Factor betaIn vivoInternal medicinemedicineHumansPlateletPlatelet activationBone regenerationPlatelet-Derived Growth FactorMineralsWound HealingbiologyPlatelet CountChemistryPlatelet ActivationIn vitroInsulin-Like Growth Factor Binding Protein 1CytokineEndocrinologyBone SubstitutesImmunologybiology.proteinCytokinesCollagenOral SurgeryWound healingPlatelet-derived growth factor receptorClinical Oral Implants Research
researchProduct

Treat and extend versus fixed regimen in neovascular age related macular degeneration: A systematic review and meta-analysis

2020

Purpose: To compare efficacy of treat and extend (T&E) versus fixed regimen treatment protocols in neovascular age-related macular degeneration (nAMD). Methods: Randomized clinical trials (RCTs) comparing T&E versus fixed regimen protocols for nAMD were systematically searched. Primary outcome was to compare the mean best corrected visual acuity (BCVA) change in T&E regimen versus fixed regimen. Secondary outcomes were change in the mean optical coherence tomography (OCT) central retinal thickness (CRT) and mean number of injections. Standardized mean difference (SMD) along with 95% confidence intervals (CIs) were calculated. Random-effect models were used for meta-analyses. Res…

Vascular Endothelial Growth Factor Amedicine.medical_specialtyretinaretinal pathology/researchVisual AcuityAngiogenesis InhibitorsTreat and extendlaw.inventionMacular DegenerationRandomized controlled trialClinical Protocolsretina – medical therapieslawInternal medicineAge relatedRanibizumabMedicineHumansbusiness.industryAge-related macular degenerationGeneral MedicineMacular degenerationpediatric ophthalmologyretina – medical therapiemedicine.diseaseOphthalmologyRegimenTreatment OutcomeMeta-analysisvitreous/retinal diseaseIntravitreal InjectionsWet Macular DegenerationPediatric ophthalmologypharmacologybusinessTomography Optical CoherenceAge-related macular degeneration; pediatric ophthalmology; pharmacology; retina; retina – medical therapies; retinal pathology/research; vitreous/retinal disease
researchProduct

Heart infarct in NOD-SCID mice: therapeutic vasculogenesis by transplantation of human CD34+ cells and low dose CD34+KDR+ cells

2004

Hematopoietic (Hem) and endothelial (End) lineages derive from a common progenitor cell, the hemangioblast: specifically, the human cord blood (CB) CD34+KDR+ cell fraction comprises primitive Hem and End cells, as well as hemangioblasts. In humans, the potential therapeutic role of Hem and End progenitors in ischemic heart disease is subject to intense investigation. Particularly, the contribution of these cells to angiogenesis and cardiomyogenesis in myocardial ischemia is not well established. In our studies, we induced myocardial infarct (MI) in the immunocompromised NOD-SCID mouse model, and monitored the effects of myocardial transplantation of human CB CD34+ cells on cardiac function.…

Vascular Endothelial Growth Factor AneoangiogenesisTime FactorsAngiogenesisCell TransplantationHeart VentriclesCD34Myocardial InfarctionAntigens CD34ApoptosisMice SCIDBiologySCIDPeripheral blood mononuclear cellBiochemistryCulture Media Serum-FreeSerum-FreeCell FusionMiceVasculogenesisMice Inbred NODparasitic diseasesGeneticsAnimalsHumansVentricular Functionendothelial precursorsCell LineageProgenitor cellAntigensMolecular Biologyneoangiogenesis endothelial precursors hematopoietic stem cellsHemodynamicsFetal BloodVascular Endothelial Growth Factor Receptor-2Coculture Techniqueshematopoietic stem cellsCulture MediaTransplantationAutocrine CommunicationCord bloodImmunologycardiovascular systemCancer researchHemangioblastInbred NODCD34neoangiogenesis; endothelial precursors; hematopoietic stem cells; Animals; Antigens CD34; Apoptosis; Autocrine Communication; Cell Fusion; Cell Lineage; Coculture Techniques; Culture Media Serum-Free; Fetal Blood; Heart Ventricles; Hemodynamics; Humans; Mice; Mice Inbred NOD; Mice SCID; Myocardial Infarction; Time Factors; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Ventricular Function; Cell Transplantation; Biotechnology; Biochemistry; Molecular Biology; GeneticsBiotechnology
researchProduct